Regulatory approval

Published by the Health Service Executive. Approved

Treatement of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count <= 10x10^9/L)

This is written in the approval document.

Reimbursement

Hospital

Citation

Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6962/356_v4_ATRA_-Arsenic_trioxide_Induction_Therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) PML::RARA APL with PML-RARA Arsenic trioxide